Publications

• Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
  Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., Maziarz, R. T., … Maloney, D. G. (2008). Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 26(2), 211–17.
• Outcomes of allogeneic hematopoietic cell transplantation (HCT) after non-myeloablative conditioning in relapsed diffuse large B-cell lymphoma (DLBCL)
  Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Forman, S. J., Agura, E., … Maloney, D. G. (2007). Outcomes of allogeneic hematopoietic cell transplantation (HCT) after non-myeloablative conditioning in relapsed diffuse large B-cell lymphoma (DLBCL). BLOOD, 110(11), 892A–892A.
• Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
  Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Bouvier, M. E., Sahebi, F., … Maloney, D. G. (2008). Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. BRITISH JOURNAL OF HAEMATOLOGY, 143(3), 395–403.
• Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies Rezvani, A. R., & Storb, R. (2008). Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. EXPERT OPINION ON BIOLOGICAL THERAPY, 8(2), 161–179.
  
• Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation Rezvani, A. R., & Storb, R. F. (2008). Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. JOURNAL OF AUTOIMMUNITY, 30(3), 172–179.
  
• Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease Flowers, M. E. D., Storer, B., Carpenter, P., Rezvoni, A. R., Vigorito, A. C., Campregher, P. V., … Martin, P. J. (2008). Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14(12), 1380–1384.
  
• Allogeneic hematopoietic cell transplantation: the state of the art Gyurkocza, B., Rezvani, A., & Storb, R. F. (2010). Allogeneic hematopoietic cell transplantation: the state of the art. EXPERT REVIEW OF HEMATOLOGY, 3(3), 285–299.
  
• Rituximab resistance Rezvani, A. R., & Maloney, D. G. (2011). Rituximab resistance. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 24(2), 203–216.
  
• Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients Yeh, R. F., Pawlikowski, M. A., Blough, D. K., McDonald, G. B., O'Donnell, P. V., Rezvani, A., … McCune, J. S. (2012). Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(2), 265–272.
  
• Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation Rezvani, A. R., Storer, B. E., Storb, R. F., Mielcarek, M., Maloney, D. G., Sandmaier, B. M., … McDonald, G. B. (2011). Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1594–1601.
  
• The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation Scott, B. L., Gooley, T. A., Sorror, M. L., Rezvani, A. R., Linenberger, M. L., Grim, J., … Deeg, H. J. (2012). The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. BLOOD, 119(11), 2657–2664.
  
• Prevention of graft-vs.-host disease Rezvani, A. R., & Storb, R. F. (2012). Prevention of graft-vs.-host disease. EXPERT OPINION ON PHARMACOTHERAPY, 13(12), 1737–1750.
  
• Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes Rezvani, A. R., McCune, J. S., Storer, B. E., Batchelder, A., Kida, A., Deeg, H. J., & McDonald, G. B. (2013). Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(7), 1033–1039.
  
• Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target. Sato, M., Storb, R., Loretz, C., Stone, D., Mielcarek, M., Sale, G. E., … Graves, S. S. (2013). Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target. Transplantation, 96(1), 34–41.
  
• Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes Rezvani, A. R., & Sandmaier, B. M. (2013). Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes. CURRENT OPINION IN HEMATOLOGY, 20(6), 509–514.
  
• 
  
• 
  
• 
  
• Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. BONE MARROW TRANSPLANTATION, 50(10), 1286–92.
  
• Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation Andermann, T. M., Rezvani, A., & Bhatt, A. S. (2016). Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 11(1), 19–28.
  
• 
  
• 
  
• Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S., Byrd, J. C., Hillmen, P., … Miklos, D. B. (2016). Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood.
  
• Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Weisdorf, D. J., Millard, H. R., Horowitz, M. M., Hyare, P. S., Champlin, R., Ho, V., … Eapen, M. (2017). Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer.
  
• Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. Epperla, N., Ahn, K. W., Ahmed, S., Jagasia, M., DiGilio, A., Devine, S. M., … Hamadani, M. (2017). Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. Journal of Hematology & Oncology, 10(1), 117.
  
• HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., … Rezvani, A. R. (2017). HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 1(17), 1347–57.
  
• Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W.-K., … Lowsky, R. (2016). Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(3), S204–S205.
  
• Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., … Meyer, E. (2015). Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. BLOOD, 126(23).
  
• Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., … Lowsky, R. (2018). Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. BLOOD ADVANCES, 2(6), 681–90.
  
• Viral Isolates in the Cerebrospinal Fluid of Hematopoietic Stem Cell Transplant Recipients, 2007-2015 Andermann, T., Asiimwe, E., Buckley, M., Tkachenko, E., Greene, C., Rezvani, A., & Bhatt, A. S. (2018). Viral Isolates in the Cerebrospinal Fluid of Hematopoietic Stem Cell Transplant Recipients, 2007-2015. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3), S378–S379.
  
• Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells Meyer, E., Laport, G. G., Tantsura, I., Tang, S. W., Sahaf, B., Rangarajan, K., … Negrin, R. S. (2018). Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3), S145.
  
• Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., … Levy, R. (2015). Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. BLOOD, 126(23).
  
• 
  
• 
  
• Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., … Johnston, L. (2017). Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(10), 1744–48.
  
• Immune Characterization of Ibrutinib Therapy Following Allohct That Provides GVL Benefit without Gvhd Sahaf, B., Ryan, C. E., Rezvani, A., Nakasone, H., Otani, J., Coutre, S., … Miklos, D. B. (2016). Immune Characterization of Ibrutinib Therapy Following Allohct That Provides GVL Benefit without Gvhd. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(3), S412.
  
• 
  
• Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors Spinner, M. A., Vina, M. F., Elder, L., Arai, S., Johnston, L., Meyer, E., … Rezvani, A. R. (2016). Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors. BLOOD, 128(22).
  
• Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., … Lowsky, R. (2016). Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation. BLOOD, 128(22).
  
• Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. Epperla, N., Ahn, K. W., Litovich, C., Ahmed, S., Battiwalla, M., Cohen, J. B., … Hamadani, M. (2019). Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. Journal of Hematology & Oncology, 12(1), 6.
  
• Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., … Lowsky, R. (2018). Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort. BLOOD, 132.
  
• Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., … Miklos, D. B. (2018). Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. BLOOD, 132.
  
• 
  
• Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis Logan, A. C., Herrera, A. F., Ryan, C. E., Rezvani, A. R., Kong, K. A., Faham, M., … Miklos, D. B. (2015). Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis. BLOOD, 126(23).
  
• Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation Ryan, C. E., Logan, A. C., Rezvani, A., Kamdar, M., Nakasone, H., Sahaf, B., … Miklos, D. B. (2014). Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. BLOOD, 124(21).
  
• Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation Ryan, C. E., Logan, A. C., Rezvani, A., Kamdar, M., Nakasone, H., Sahaf, B., … Miklos, D. B. (2015). Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(2), S307–S308.
  
• Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning Vaughn, J., Sorror, M. L., Chauncey, T., Pulsipher, M. A., Maziarz, R. T., Maris, M. B., … Maloney, D. G. (2015). Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(2), S88–S89.
  
• Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors. Sorror, M. L., Storer, B., Sandmaier, B. M., Franke, G. N., Laport, G. G., Chauncey, T., … Maloney, D. G. (2010). Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors. BLOOD, 116(21), 553.
  
• Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation. Andermann, T. M., Rezvani, A., & Bhatt, A. S. (2016). Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation. Current Hematologic Malignancy Reports.
  
• Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI INSIGHT, 4(10).
  
• Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation. Veeraputhiran, M., Arai, S., Lowsky, R., Miklos, D. B., Meyer, E., Muffly, L. S., … Johnston, L. J. (2016). Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
  
• 
  
• Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma. Neppalli, A. K., Shizuru, J., Johnston, L. J., Muffly, L. S., Weng, W.-K., Negrin, R., … Rezvani, A. R. (2016). Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
  
• Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., … Lowsky, R. (2019). Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 3(16), 2454–64.
  
• Costs and outcomes with once-daily versus every-six-hour intravenous busulfan in allogeneic hematopoietic cell transplantation. Singhal, S., Kim, T., Jenkins, P., Bassett, B., Tierney, D. K., & Rezvani, A. R. (2019). Costs and outcomes with once-daily versus every-six-hour intravenous busulfan in allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.
  
•